Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 24Phase 1 10Phase 2/3 6Phase 1/2 6Phase NA 5Phase EARLY_PHASE1 2

Status

Terminated 4Unknown 1Completed 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 6

Conditions

Glioblastoma 5Neoplasms 3Recurrence 1Neuroectodermal Tumors 1Medulloblastoma 1Brain Neoplasms 1

Interventions

Temozolomide 102Radiotherapy 47Bevacizumab 33Carboplatin 23Irinotecan 20pembrolizumab 17Radiosurgery 16Nivolumab 16Radiation 14Cyclophosphamide 11Magnetic Resonance Spectroscopy 10fludarabine 8Trastuzumab 8Radiotherapy, Intensity-Modulated 8Carmustine 8Surgical Procedures, Operative 7Specimen Handling 7Pemetrexed 7Paclitaxel 7Interleukin-2 7Filgrastim 7Everolimus 7Erlotinib Hydrochloride 7temsirolimus 6Vorinostat 6Radiotherapy, Conformal 6Lomustine 6Ipilimumab 6Granulocyte-Macrophage Colony-Stimulating Factor 6Gemcitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1/2 × Lomustine × CNS × Clear all
NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

VBI Vaccines Inc.

Phase 1/2 Terminated
70 enrolled
CNS

Glioblastoma, Neoplasms

NCT04421378 2024-12-16

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Karyopharm Therapeutics Inc

Phase 1/2 Terminated
74 enrolled 23 charts
CNS

Glioblastoma

NCT04573192 2024-04-08

GLIOSTAR

Philogen S.p.A.

Phase 1/2 Unknown
142 enrolled
CNS

Glioblastoma

NCT02765165 2021-07-23

Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)

Proximagen, LLC

Phase 1/2 Terminated
26 enrolled 20 charts
CNS

Brain Neoplasms, Glioblastoma, Neoplasms, Recurrence

NCT01614132 2020-03-31

NOA-07

University of Regensburg

Phase 1/2 Completed
33 enrolled
CNS

Medulloblastoma, Neoplasms, Neuroectodermal Tumors

NCT00948389 2012-08-31

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Bristol-Myers Squibb

Phase 1/2 Terminated
28 enrolled 16 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡